Omega-3 Prescription Drugs Market Size & Share 2024-2032

Omega-3 Prescription Drugs Market Size

Omega-3 Prescription Drugs Market size was valued at around USD 1.4 billion in 2023 and is estimated to grow at 8.2% CAGR from 2024 to 2032. Omega-3 prescription drugs are pharmaceutical formulations containing highly purified omega-3 fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), used to treat or manage conditions like cardiovascular diseases, metabolic disorders, and certain inflammatory or neurological conditions.

The rising prevalence of cardiovascular diseases is a significant driving factor for the market. For instance, according to a report from the World Heart Federation (WHF), global deaths from cardiovascular disease (CVD) surged to 20.5 million in 2021. CVD was the leading cause of death worldwide in 2021, with 80% of these deaths occurring in low- and middle-income countries (LMICs). This underscores the growing need for effective treatments, such as omega-3 prescription drugs, to address and manage cardiovascular conditions and improve global health outcomes.
 

Furthermore, growing awareness of health benefits, advancements in research and development, and a rising geriatric population are key factors driving the market's growth.
 

Omega-3 Prescription Drugs Market Trends

Advancements in research and development (R&D) for omega-3 prescription drugs are significantly enhancing their therapeutic potential and expanding their applications. Cutting-edge innovations in purification and formulation technologies are leading to highly concentrated omega-3 preparations with improved bioavailability and efficacy.
 

• Advances in purification technologies have led to the development of highly concentrated and purified omega-3 formulations. These improved formulations aim to maximize the therapeutic benefits of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) while minimizing potential side effects.
   
• Ongoing research is exploring additional therapeutic indications for omega-3 prescription drugs beyond cardiovascular health. This includes potential benefits for neurological conditions, metabolic disorders, and inflammatory diseases. Clinical trials are assessing the efficacy of omega-3s in managing conditions such as Alzheimer's disease, rheumatoid arthritis, and diabetes.
   
• Additionally, advancements in novel drug delivery systems, including advanced encapsulation technologies, are pivotal in optimizing the efficacy of omega-3 fatty acids by improving their bioavailability and stability. As a result, patients are likely to experience enhanced therapeutic benefits and more consistent outcomes, supporting better overall health management and maximizing the impact of omega-3 supplementation, thus propelling market growth.
   

Omega-3 Prescription Drugs Market Analysis

Based on drug type, the market is divided into vascepa, lovaza, and other drug types. The vascepa segment of the market is forecasted to reach USD 1.3 billion by 2032.
 

• Vascepa consists of pure eicosapentaenoic acid (EPA) in a highly concentrated and refined form. This purity ensures a higher dose of EPA without the contaminants often found in less purified omega-3 supplements, enhancing its effectiveness.
   
• Vascepa has demonstrated strong clinical efficacy in reducing elevated triglyceride levels, a key risk factor for cardiovascular disease. Clinical studies, such as the REDUCE-IT trial, have shown that Vascepa significantly lowers the risk of major cardiovascular events, including heart attacks and strokes.
   
• Moreover, as a prescription medication, Vascepa undergoes stringent quality control and manufacturing processes to ensure purity and consistency in dosage. This level of standardization provides more reliable outcomes compared to over-the-counter omega-3 supplements, which may vary in quality and efficacy, thereby driving market growth in the omega-3 prescription drugs sector.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on application, the omega-3 prescription drugs market is segmented into cardiovascular diseases, diabetes, neurological disorders, and other applications. The cardiovascular diseases segment accounted for USD 643.9 million in 2023.
 

• Omega-3 fatty acids possess anti-inflammatory properties that help reduce inflammation throughout the body, including in the blood vessels. Chronic inflammation is a key contributor to the development and progression of cardiovascular diseases, so reducing inflammation can improve heart health.
   
• These drugs are known to lower triglyceride levels. High triglycerides are a significant risk factor for cardiovascular diseases, including heart disease and stroke. Prescription omega-3 drugs like Vascepa are specifically formulated to significantly reduce triglyceride levels, thereby lowering the risk of cardiovascular events.
   
• Additionally, omega-3 may help reduce blood pressure, particularly in individuals with hypertension. Lowering blood pressure reduces strain on the cardiovascular system and decreases the risk of heart disease and stroke, which is driving revenue growth in this segment.
   

Based on distribution channel, the omega-3 prescription drugs market is bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is forecasted to reach USD 1.2 billion by 2032.
 

• Hospital pharmacists possess specialized knowledge and expertise in managing complex medication regimens, including omega-3 prescription drugs. They can provide in-depth consultations on drug interactions, dosage adjustments, and patient-specific considerations.
   
• Hospital pharmacists are trained professionals who can offer personalized advice and recommendations based on individual health needs and conditions. They can assist consumers in selecting the appropriate omega-3 prescription drugs and provide guidance on proper usage.
   
• Moreover, hospital pharmacies ensure that omega-3 prescription drugs are available and accessible in emergency situations, providing timely access to critical medications for patients in acute care settings, thereby driving market growth.
   

The growth of the omega-3 prescription drugs market in the U.S., is projected to reach USD 1.1 billion by 2032.
 

• The U.S. Food and Drug Administration (FDA) provides rigorous oversight and approval processes for omega-3 prescription drugs, ensuring that these medications meet high standards for safety, efficacy, and quality. This builds consumer confidence and supports market growth.
   
• The rising incidence of diabetes significantly contributes to the market's expansion. For instance, according to the Public Health Agency of Canada, approximately 9.4% of the population, or 3.7 million individuals, were diagnosed with diabetes in 2021, with a prevalence of 10% in males and 8.7% in females.
   

The omega-3 prescription drugs market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The UK faces a notable burden of diabetes. For instance, data from The British Diabetic Association revealed that more than 4.3 million people in the UK were managing with diabetes, while 850,000 people have diabetes but remain to undiagnosed in 2021.
   
• The UK is a center for medical research and innovation, including studies on Omega-3 fatty acids. Ongoing research and clinical trials contribute to the development of new omega-3 prescription drugs and enhance the understanding of their benefits.
   

Japan omega-3 prescription drugs market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan boasts a well-developed healthcare system with high standards of medical care. This infrastructure supports the prescription and management of omega-3 drugs as part of advanced therapeutic regimens.
   
• There is a high level of public awareness regarding the health benefits of omega-3 fatty acids. This awareness is supported by educational campaigns and positive scientific research, leading to greater acceptance and demand for these drugs.
   

The omega-3 prescription drugs market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• There is a growing awareness among healthcare professionals and the public about the benefits of omega-3 fatty acids for cardiovascular health. This awareness drives demand for omega-3 prescription medications as part of comprehensive health management.
   

Omega 3 Prescription Drugs Market Share

The omega-3 prescription drugs sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. Key to market strategy is the consistent launch of innovative products, utilizing a range of technologies. Major industry leaders wield significant influence, spearheading progress with hefty investments in R&D. Furthermore, strategic partnerships and M&A activities play a crucial role in bolstering market standing and broadening global reach, especially in the face of changing regulations.
 

Omega-3 Prescription Drugs Market Companies

Some of the eminent market participants operating in the omega-3 prescription drugs industry include:

• AstraZeneca plc
• Amarin Corporation plc
• Camber Pharmaceuticals, Inc.
• Dr. Reddy’s Laboratories Ltd.
• GSK plc
• Grupo Ferrer Internacional, S.A.
• Hikma Pharmaceuticals PLC
• Natco Pharma Limited
• Pfizer Inc.
• Viatris Inc.
• Zydus Lifesciences Limited
   

Omega-3 Prescription Drugs Industry News:

• In January 2023, AstraZeneca acquired CinCor Pharma, Inc., a biopharmaceutical company. This acquisition enabled AstraZeneca to significantly bolster its cardiovascular portfolio by integrating CinCor’s innovative hypertension therapies, thereby enhancing its research and development capabilities.
   

The omega-3 prescription drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Vascepa
• Lovaza
• Other drug types

Market, By Application

• Cardiovascular diseases
• Diabetes
• Neurological disorders
• Other applications

Market, By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa